Teva Pharmaceutical Industries (NYSE:TEVA) saw its stock price move up 14% over the last week, a notable jump attributed ...

The general mood among these heavyweight investors is divided, with 44% leaning bullish and 33% bearish. Among these notable options, 5 are puts, totaling $256,004, and 4 are calls, amounting to ...

HighTower Advisors LLC raised its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 32.3% in ...

The global pharmaceutical company Teva announced a strategic partnership with Kerry Pharma, a subsidiary of the Kerry ...

As a drugmaker depending heavily on sales of both branded and non-branded products, Teva has said that it is uniquely affected by how medicines are selected for the Medicare drug price negotiation | ...

In the third quarter, Teva brand net sales fell 6% year over year to $24.1 million, while parent company Deckers overall ...

Francis, who is currently CEO of gene therapy specialist Purespring Therapeutics and cardiovascular drug developer company Forcefield Therapeutics, is due to take the top job at Teva on 1 January ...

Teva Pharmaceutical Industries Limited develops ... and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory ...

TEVA): Traditionally known as a generic drug company, Teva has a growing branded drug business and a promising pipeline. Following a period of poor capital allocation decisions by prior management ...

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Free Report) have been assigned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, ...

Bullish option flow detected in Teva (TEVA) with 17,095 calls trading, 1.7x expected, and implied vol increasing over 1 point to 42.32%. 3/14 ...

These widely traded and volatile stocks may make fireworks in the months ahead.